To examine whether or not TRPC5 can serve as a noninvasive biomarker for the imaging examination of chemoresistance, Wang et al.[97] analyzed plasma from 131 BC patients and the corresponding tumor tissue from 54 patients before anthracycline/taxane-based chemotherapy. Here, TRPC5 is linked to neoplasm.